Introduction
Cisplatin was first synthesized by M. Peyrone in 1844 and its chemical structure was first elucidated by Alfred Werner in 1893. However, the compound did not gain sufficient scientific investigations until the 1960’s, when Rosenberg found that it was capable of inhibiting cell division in Escherichia coli, which increase the possibility of its use in cancer chemotherapy [
1,
2].
In 1978, cisplatin became the first FDA-approved platinum compound for cancer treatment [
3], and later it became one of the most important anticancer drugs. Nowadays, platinum-based chemotherapy remains an important treatment modality for these patients with advanced NSCLC due to the emergence of resistance to targeted therapies of EGFR, ALK, or ROS mutant tumors [
4].
For the mechanism of its pharmacology, generally, they damage DNA, leading to cell cycle arrest and cell death, typically via apoptosis [
5,
6]. However, side effects and drug resistance are the two inherent challenges of cisplatin that limit its application and effectiveness [
7]. In many common tumor types such as NSCLC, the therapeutic efficacy of platinum-based DNA damaging agents is limited, resulting in only about one-third of patients receive benefits [
8,
9]. By now, at least four distinct classes of mechanisms by which cancer cells become resistant to cisplatin-based chemotherapy have been developed and targeting at least two distinct mechanisms might be the most successful strategies for circumventing resistance [
10].
In this study, we aim to find out the causes of resistance to cisplatin from the genetic, pharmacological, and cellular level as well as the prognosis of patients who have undergone platinum-based chemotherapy, and provide a reference for therapeutic decisions in clinical treatments.
Methods
Data processing
Details of cell lines information were downloaded from Cancer Dependency Map (Depmap, depmap.org) and Cancer Cell Line Encyclopedia (CCLE,
https://portals.broadinstitute.org/ccle/data), including IC50 value, cell line source, somatic mutation, mRNA expression, miRNA expression, and metabolite. The information of lung adenocarcinoma patients treated with cisplatin was downloaded from The Cancer Genome Atlas (TCGA,
https://gdc.cancer.gov/) (TCGA-LUAD) with their gene expression data. As the CCLE, Depmap, TCGA databases are open to the public under specific guidelines, it confirms that all written informed consents were obtained before data collection.
Differential analysis
Differential analysis of somatic mutation, RNA, miRNA, and metabolite data between low IC50 and high IC50 groups was performed with R (version 3.6.1). Maftools, the R package, was used to summarize, analyze and visualize the somatic mutation data. RNA, miRNA, and metabolite data were first normalized and standardized by constructing relevant expression matrices using edgfR after removing those without enough sequence fragments in the sample. Differential genes, somatic mutations, miRNAs (P < 0.05, false discovery rate (FDR) < 0.05) were sorted according to logFoldChange values (|logFC|> 1) to identify significantly different expressions. All the differential analyses were presented in a heat map and volcano plots.
GO, KEGG and GSVA analyses
GO analysis and GSVA analysis were performed to investigate the biological implications of proteins significantly associated with platinum response. R (version 3.6.1) was used for GSVA as well as GO and KEGG pathway enrichment analyses. The significance level was set to 0.05 for the corrected P-values. Bar map and dot map were used to visualize the consequences.
Model contribution
The characteristic of LASSO regression is to consider both Variable Selection and Regularization when fitting a generalized linear model, for applying which, the "Glmnet" (Lasso and Elastic-Net Regularized Generalized Linear Models) R package via penalized maximum likelihood fitness was used, and the mRNAs and miRNAs mostly relative to the resistance to cisplatin were obtained.
Logistic regression, classification and regression tree (CART), and C4.5 decision tree classification algorithm, which use occurrence ratio to determine the category of the dependent variable, was based on the results of LASSO. Finally, we use stepwise regression to select variables, and contribute the predictable model.
Cell culture and cytotoxic assay
NSCLC A549 and H358 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were fostered in RPMI-1640 containing 10% fetal bovine serum (FBS) and 100 μg/mL of penicillin–streptomycin with or without DDP (Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) added into the culture medium for incubation in a humid atmosphere containing 5% CO2 at 37 °C.
Cell proliferation was evaluated by Cell Counting Kit-8(CCK-8; Dojindo, Kumamoto, Japan). Briefly, 2 × 103 of A549 and H358 cells were plated in 96 well plates. They were incubated with 100 μL RPMI-1640 containing 10% fetal bovine serum (FBS) and 100 μg/mL of penicillin–streptomycin for 24 h, then with or without DDP (Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) for another 24 h at 37 °C. After treatment, cells were incubated in 10% CCK-8 reagent. The OD value was measured after 2 h at 450 nm with a microplate reader from Bio-Rad (Microplate reader 3550-UV).
RNA interference
siRNAs targeting BATF3, IRF5, ZBTB38, and Silencer Negative Control siRNAs were purchased from Ribobio (sequences provided in Additional file
6: Table S1). We purchased two different siRNAs for each gene to avoid the off-target effects. A549 and H358 cells were seeded in 6-well plates for 24 h prior to transfection with siRNA targeting BATF3, IRF5, ZBTB38, and corresponding non-targeting controls. A total of 150 nM of siRNA was added to each experiment made up of the target siRNA and topped up with the appropriate concentration of non-targeted controls where appropriate. Transfections were carried out in OptiMem medium (Gibco) using Lipofectamine 8000 transfection reagent (Beyotime). 48 h post-transfection, cells were harvested and assayed for RNA and protein expression levels of the target of interest. At the same time, corresponding samples were treated as described in the text.
RNA preparation and qRT-PCR analysis
To detect the expression of BATF38, IRF5, ZBTB38 in A549 and H358 cell lines, RT-qPCR was carried out on an QuantStudio® 5 real-time PCR system (Applied Biosystems) with proper PCR parameters.
Total RNAs were extracted by TRIzol (TIANGEN, Beijing, China). The first-strand cDNA was synthesized using Hifair® III 1st Strand cDNA Synthesis SuperMix for qPCR (gDNA digester plus) (YEASEN, Tokyo, Japan) according to the manufacturer's instructions. Then Hieff
® qPCR SYBR Green Master Mix (Low Rox Plus) (YEASEN) was used with the following PCR parameters, 1 cycle of 30 s at 95 °C, 40 cycles of 5 s at 95 °C and 34 s at 60 °C. β-actin was used as the reference. Primers used in this study are listed in Additional file
7: Table S2.
All the samples were repeated three times.
Western blot analysis
Proteins of A549 cells and H358 cells after RNA interference were extracted using RIPA (Beyotime, Shanghai, China) with protease and phosphatase inhibitor cocktail (Topscience). Then these proteins were quantified by Enhanced BCA Protein Assay Kit (Beyotime). Proteins were then resolved, separated, and finally transferred into PVDF membranes under the influence of an electric current in a procedure (Merck-Millipore, Burlington, MA, USA). Membranes were blocked, followed by incubation with specific primary antibodies [
11].
Finally, we observed the protein bands by Moon chemiluminescence kit (Beyotime). The following antibodies were used: Rabbit anti-BATF3 (NBP2-41296, dilution 1:1,500, Novus Biologicals); Rabbit anti-IRF5 (CY5822, dilution 1:1,500, Abways); rabbit anti-ZBTB38 (21906–1-AP, dilution 1: 1,500, Proteintech), mouse β-ACTIN (1:3,000, AA128, Beyotime), horseradish peroxidase (HRP)-labeled goat anti-rabbit IgG (H + L) (1:3,000, A0208, Beyotime), and HRP-labeled goat anti-mouse IgG (H + L) (1:3,000, A0208, Beyotime).
Single tumor and immune cells
We used the same methods described in our previous studies to test cisplatin-sensitivity-related genes [
12].
This study was approved by the Ethics Committee of Zhongshan Hospital, Fudan University (B2019–137R). Patients had signed the informed consent at hospitalization.
Discussion
Cisplatin is one of the most potent and widely used drugs for the treatment of various solid cancers such as testicular, lung, cervical cancer, etc., [
7], while tumor responses to cisplatin or carboplatin depend on the levels of platinum–DNA adducts and the DNA repair capacity of the cells [
3,
15]. The development of cisplatin resistance in human cancer cells, including cell growth-promoting, apoptosis, DNA damage repair, and endocytosis, all of which are mechanisms supporting cell survival [
16].
In this study, we began with exploring the important genes and miRNA of different cancer cell lines related to the IC50 value of cisplatin, based on which, we constructed the predicting model of the cisplatin resistance using the expressing value of 6 mRNAs, 3 of which, BATF3, IRF5, ZBTB38 were also verified in our own samples. All of them are closely related to the immune.
On the one hand, several studies reported that chemotherapy was able to modulate the function of TAM [
17‐
19]. On the other hand, the different alteration of TAM reflects patients’ responses to chemotherapy [
20‐
23]. Coincidentally, the three genes we selected are all related to immunity, which might suggest that they affect tumor cell sensitivity to cisplatin by regulating TAM. The interaction between BATFs and IRFs in immune cell lineages occurs in the gene expression network of several crucial processes. For example, BATF and IRF4 cooperate in CSR, as well as in antibody class switching through influencing T
FH cells and germinal center B cells [
24]. What’s more, the cooperation of ZBTB46, BATF3, and IRF8 activates the development of CD8α+ conventional dendritic cells (cDCs) [
25]. In this study, we found ZBTB38, BATF3, and IRF5 might have interactions that affect the cell sensitivity to cisplatin, but with various trends.
Basic leucine zipper transcription factor ATF-like (BATF), BATF2, and BATF3 belong to the activator protein 1 (AP-1) family of transcription factors, which regulate numerous cellular processes [
26]. BATF3 was first identified in human T cells and was later found to play a critical role in the development of the cDC1 subset of conventional DCs [
25,
27]. Although we found that knocking down the expression of BATF3 will increase cancer’s sensitivity to cisplatin, the main function of this transcription factor is to activate CD8alpha+ dendritic cells. In other words, it plays important role in cross-presentation in tumor rejection and deletion of the transcription factor Batf3 ablated development of CD8alpha + dendritic cells [
28]. Furthermore, within the OpACIN trial, severe melanoma patients suffering from the reoccurrence of tumor after adjuvant or neoadjuvant consisting ipilimumab + nivolumab displayed a low level of Batf3
+ DC-associated genes [
29], which might reveal the two-side adjusting effects of BATF3 on chemotherapy and immunotherapy.
Interferon regulatory factor-5 (IRF5) is a transcription factor and has essential cellular mechanisms as a tumor suppressor gene [
30]. The beneficial effects of NACRT on TAMs’ infiltration might be associated with gender-dependent IRF-5 expression, as CD163 + TAMs, which were related to poor prognosis[
31], were shown to be negatively correlated with the number of IRF-5 + cells[
20]. It was also reported that increased expression of IRF-5 in M2-like TAM promoted antitumor immune response to NACT [
31]. In our research, IRF-5 showed the same tendency as the knocking down of it could increase tumor cell's resistance to cisplatin with a higher IC50, and the potential mechanism might lie on its function of secretin IFN-α, because the delivery of IRF5 protein into human primary pDCs increased IFN-α secretion [
32], which has antiproliferative, differentiation-inducing, apoptotic, and antiangiogenic properties, and its clinical activity has been demonstrated in several cancers, including as post-chemotherapy maintenance [
33,
34].
Zinc finger and BTB domain-containing 38 (ZBTB38) represents one member of the zinc finger (ZF) family of Methyl-CpG-binding proteins (MBPs) [
35]. Similar to the IRF5, in our experiment, its expression is related to cisplatin sensitivity. Previous study showed that ZBTB38 can enhance the response to DNMT inhibitor therapies as a target of DNA methyltransferase inhibitor [
36] as well as it can influence response of cancer cell lines to chemotherapy through involving in diverse epigenetic processes affecting DNA methylation [
37]. However, The biological function of ZBTB38 remains also elusive [
38]. In bladder cancer, ZBTB38 promotes migration and invasive growth [
39], while in prostate cancer, depletion of ZBTB38 results in higher expression of ROS and elevated cell death after doxorubicin treatment [
40].
However, the specific mechanism among those 3 genes, with which cancer cells' sensitivity to cisplatin could be changed, still needs to be explored.
miRNAs could modulate about 30% of gene expression through influencing mRNA translation [
41], which play a key role in many biological processes, including tumor chemoresistance [
42]. Evidence has shown that the expression of several miRNAs may relate to cisplatin resistance in malignant cells [
43,
44]. In our study, miR-200c and miR-203 finally contributed to the cisplatin-resistance model. The former, which belongs to the miR-200 family, is reported that it could increase the sensitivity of cells to antitumor medications in a variety of cancers, including gastric [
45,
46], breast [
47], and non-small cell lung cancer [
48]. Similarly, miR-203 was differentially expressed in DDP-sensitive and -insensitive tumor cells. Previous study has demonstrated that miR-203 could bind to the 3′UTR of DKK1 and then regulate the characteristics of lung cancer cells [
49]. Furthermore, it also affects cisplatin resistance of pancreatic cancer cells [
50], tongue squamous cancer [
51]. In all, large numbers of surveys indicate that miRNAs actively affect the mechanism of cisplatin resistance.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.